Kevin Perez holds a MS in Computer Science from New York University (NYU) and a MS in Biomedical Sciences from Paris Descartes University. He is interested in biomedical data analysis and bringing the latest biomedical research news to patients.
Non-small cell lung cancer patients in England and Wales who failed prior chemotherapy can now access Opdivo (nivolumab) as a second-line ... Read more
In just three years, Bristol-Myers Squibb (BMS) received more than 10 approvals for Opdivo (nivolumab), authored 12 publications in the New England Journal of ... Read more
The first patient has been dosed in a Phase 1b/2 trial evaluating Imugene’s stomach cancer vaccine HER-Vaxx. Researchers are still recruiting participants. ... Read more
Bristol-Myers Squibb has formed a partnership with Japan’s Daiichi Sankyo to test Opdivo (nivolumab) in combination with DS-8201 in HER2-positive metastatic breast and bladder cancer. Opdivo, ... Read more
